US Bancorp DE trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 209,651 shares of the medical research company’s stock after selling 976 shares during the quarter. US Bancorp DE’s holdings in Thermo Fisher Scientific were worth $95,681,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in shares of Thermo Fisher Scientific by 2.2% in the fourth quarter. BlackRock Inc. now owns 29,504,221 shares of the medical research company’s stock valued at $13,742,475,000 after buying an additional 624,512 shares in the last quarter. FMR LLC lifted its position in shares of Thermo Fisher Scientific by 5.6% during the fourth quarter. FMR LLC now owns 13,022,987 shares of the medical research company’s stock valued at $6,065,847,000 after purchasing an additional 686,768 shares in the last quarter. Morgan Stanley lifted its position in shares of Thermo Fisher Scientific by 4.4% during the fourth quarter. Morgan Stanley now owns 7,726,428 shares of the medical research company’s stock valued at $3,598,815,000 after purchasing an additional 328,820 shares in the last quarter. Norges Bank bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $2,336,640,000. Finally, Nuveen Asset Management LLC increased its holdings in Thermo Fisher Scientific by 10.1% during the fourth quarter. Nuveen Asset Management LLC now owns 2,084,813 shares of the medical research company’s stock worth $971,065,000 after buying an additional 192,107 shares during the last quarter. 87.17% of the stock is currently owned by hedge funds and other institutional investors.
Thermo Fisher Scientific stock traded down $6.06 during mid-day trading on Tuesday, reaching $461.32. The stock had a trading volume of 11,873 shares, compared to its average volume of 1,796,376. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.93 and a quick ratio of 2.31. The company has a market capitalization of $181.31 billion, a price-to-earnings ratio of 38.31, a PEG ratio of 1.40 and a beta of 0.85. The company has a 50-day moving average price of $468.08 and a two-hundred day moving average price of $476.02. Thermo Fisher Scientific Inc. has a one year low of $324.35 and a one year high of $532.57.
The business also recently announced a quarterly dividend, which was paid on Friday, April 16th. Shareholders of record on Tuesday, March 16th were paid a dividend of $0.26 per share. The ex-dividend date of this dividend was Monday, March 15th. This represents a $1.04 annualized dividend and a yield of 0.23%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. Thermo Fisher Scientific’s dividend payout ratio is currently 8.42%.
TMO has been the subject of a number of research analyst reports. Citigroup raised their price objective on shares of Thermo Fisher Scientific from $500.00 to $530.00 and gave the stock a “buy” rating in a report on Tuesday, February 2nd. Credit Suisse Group lifted their target price on shares of Thermo Fisher Scientific from $556.00 to $580.00 in a research note on Tuesday, January 12th. Evercore ISI lifted their target price on shares of Thermo Fisher Scientific from $525.00 to $540.00 and gave the stock an “outperform” rating in a research note on Thursday, April 22nd. Barclays began coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 8th. They issued an “overweight” rating and a $525.00 target price for the company. Finally, Stifel Nicolaus lifted their target price on shares of Thermo Fisher Scientific from $530.00 to $600.00 and gave the stock a “buy” rating in a research note on Tuesday, February 2nd. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $534.45.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.